EA201792492A1 - Aml-антигены и их применение - Google Patents

Aml-антигены и их применение

Info

Publication number
EA201792492A1
EA201792492A1 EA201792492A EA201792492A EA201792492A1 EA 201792492 A1 EA201792492 A1 EA 201792492A1 EA 201792492 A EA201792492 A EA 201792492A EA 201792492 A EA201792492 A EA 201792492A EA 201792492 A1 EA201792492 A1 EA 201792492A1
Authority
EA
Eurasian Patent Office
Prior art keywords
application
aml
antigens
cells
present
Prior art date
Application number
EA201792492A
Other languages
English (en)
Inventor
Херген СПИТС
Марейн Алетта Гиллиссен
Мартейн Кедде
Метте Дебора Хазенберг
Паула Мария Вильхельмина Ван Хелден
Ваутер Пос
Original Assignee
Аимм Терапьютикс Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аимм Терапьютикс Б.В. filed Critical Аимм Терапьютикс Б.В.
Publication of EA201792492A1 publication Critical patent/EA201792492A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Abstract

В настоящем изобретении предложены новые соединения, содержащие антиген AML-клеток, и их применения.
EA201792492A 2015-06-24 2016-06-24 Aml-антигены и их применение EA201792492A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15173662 2015-06-24
EP16150621 2016-01-08
PCT/NL2016/050449 WO2016209079A1 (en) 2015-06-24 2016-06-24 Aml antigens and uses thereof

Publications (1)

Publication Number Publication Date
EA201792492A1 true EA201792492A1 (ru) 2018-07-31

Family

ID=56567655

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792492A EA201792492A1 (ru) 2015-06-24 2016-06-24 Aml-антигены и их применение

Country Status (14)

Country Link
US (2) US11524989B2 (ru)
EP (1) EP3313870B1 (ru)
JP (2) JP7010704B2 (ru)
KR (1) KR20180118101A (ru)
CN (1) CN107810191B (ru)
AU (2) AU2016281424B2 (ru)
BR (1) BR112017027677A2 (ru)
CA (1) CA2989551A1 (ru)
DK (1) DK3313870T3 (ru)
EA (1) EA201792492A1 (ru)
HK (1) HK1247934A1 (ru)
MX (1) MX2017016258A (ru)
TW (1) TWI751110B (ru)
WO (1) WO2016209079A1 (ru)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399847B1 (en) * 1996-11-25 2008-07-15 The General Hospital Corporation Nucleic acids encoding artificial P-selectin ligands
EP1452868A2 (en) * 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
MX2007014118A (es) 2005-05-11 2008-02-05 Dinona Inc Epitope cd43 especifico de leucemia aguda y linfoma linfoblastico y uso del mismo.
US7622560B2 (en) 2005-05-11 2009-11-24 Dinona Inc. Monoclonal antibody specific for CD43 epitope
KR100738401B1 (ko) * 2005-05-11 2007-07-11 다이노나(주) 급성백혈병- 및 림프모구 림프종 특이 ｃｄ43의항원결정부위 및 이의 용도
PL2540820T3 (pl) 2005-12-09 2018-05-30 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Środki i sposoby wpływania na stabilność komórek wytwarzających przeciwciała
US9005974B2 (en) 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
KR101496433B1 (ko) 2006-06-07 2015-02-26 바이오얼라이언스 씨.브이. 암세포 상에서 발현되는 ｃｄ-43 및 ｃｅａ 상의 에피토프를 함유하는 탄수화물을 인식하는 항체 및 이를 이용하는 방법
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
AU2008338313B2 (en) * 2007-12-18 2014-01-16 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
JP6325451B2 (ja) 2011-12-02 2018-05-16 アイム・セラピューティクス・べー・フェー Ａ型インフルエンザに特異的な抗体
KR20240042192A (ko) 2013-12-17 2024-04-01 크링 바이오테라퓨틱스 비.브이. 골수 증식성 또는 림프 증식성 질환에 대응하는 수단 및 방법

Also Published As

Publication number Publication date
TW201718631A (zh) 2017-06-01
TWI751110B (zh) 2022-01-01
JP2018520670A (ja) 2018-08-02
AU2016281424A1 (en) 2018-01-04
WO2016209079A1 (en) 2016-12-29
CA2989551A1 (en) 2016-12-29
HK1247934A1 (zh) 2018-10-05
AU2016281424B2 (en) 2020-12-24
DK3313870T3 (da) 2020-08-31
US20180170998A1 (en) 2018-06-21
AU2020294288B2 (en) 2022-05-05
EP3313870B1 (en) 2020-06-03
JP2022000038A (ja) 2022-01-04
AU2020294288A1 (en) 2021-01-28
CN107810191A (zh) 2018-03-16
CN107810191B (zh) 2023-06-13
US11524989B2 (en) 2022-12-13
US20230235018A1 (en) 2023-07-27
MX2017016258A (es) 2018-04-20
JP7010704B2 (ja) 2022-02-10
NZ738289A (en) 2021-08-27
BR112017027677A2 (pt) 2018-08-28
EP3313870A1 (en) 2018-05-02
KR20180118101A (ko) 2018-10-30
AU2020294288B9 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
EA202092435A2 (ru) Моноклональные антитела против bcma
CY1122653T1 (el) Αντισωματα αντι-τιgιτ, αντισωματα αντι-ρvrig και συνδυασμοι εξ αυτων
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201691991A1 (ru) Мультиспецифические антитела
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
EA201890493A1 (ru) РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ
EA201890712A1 (ru) Антитела к про-/латентному миостатину и их применения
CR20150482A (es) Anticuerpos e inmunoconjugados anti-b7-h4
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
EA201591137A1 (ru) Ингибиторы mk2 и их применения
BR112016018521A2 (pt) composição, e, kit.
FR3021319B1 (fr) Peptides, compositions les comprenant et utilisations notamment cosmetiques
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
EA201791992A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
EA201792000A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
TR201901228T4 (tr) Vortioksetin piroglutamat.
EA201591709A1 (ru) 5-бром-индирубины
EA201792492A1 (ru) Aml-антигены и их применение
EA201990505A1 (ru) Анти-tigit антитела, анти-pvrig антитела и их комбинации
EA201890727A1 (ru) Модуляторы взаимодействия сестрина-gator2 и их применение